Data Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of COMP360 Psilocybin Therapy to be Presented at ASCO 2023
Portfolio Pulse from Benzinga Newsdesk
COMPASS Pathways announced new long-term efficacy data of investigational COMP360 psilocybin in cancer patients with major depressive disorder will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO).
May 26, 2023 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
COMPASS Pathways' presentation of new long-term efficacy data of COMP360 psilocybin therapy at ASCO 2023 may positively impact the company's stock.
The presentation of new long-term efficacy data of COMP360 psilocybin therapy at ASCO 2023 may generate positive sentiment around COMPASS Pathways' stock. The data could potentially lead to increased interest in the company's investigational therapy and may positively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100